Of mice and men: Opportunities to use genetically engineered mouse models of synovial sarcoma for preclinical cancer therapeutic evaluation

Cancer Control

Volumn 18, Issue 3, 2011, Pages 196-203

  Jones, Kevin B ^a,b   Haldar, Malay ^c   Schiffman, Joshua D ^a,b   Cannon Albright, Lisa ^a   Lessnick, Stephen L ^a   Sharma, Sunil ^a   Capecchi, Mario R ^a   Randall, R Lor ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; FIGITUMUMAB; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; PAZOPANIB; ROMIDEPSIN; SORAFENIB; SQUALAMINE; TANESPIMYCIN; TASIDOTIN; TRABECTEDIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; GENETIC MODEL; HUMAN; NONHUMAN; SYNOVIAL SARCOMA; TRANSGENIC MOUSE; TUMOR XENOGRAFT;

EID: 79959344634     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481101800307     Document Type: Article

References (59)

1. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21(14):2719-2725.
2. Brennan B, Stevens M, Kelsey A, et al. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children's Cancer and Leukaemia Group between 1991 and 2006. Pediatr Blood Cancer. 2010;55(1):85-90.
3. Guadagnolo BA, Zagars GK, Ballo MT, et al. Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69(4):1173-1180.
4. Turc-Carel C, Dal Cin P, Limon J, et al. Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. Proc Natl Acad Sci U S A. 1987;84(7):1981-1985.
5. Clark J, Rocques PJ, Crew AJ, et al. Identifi cation of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet. 1994;7(4):502-508.
6. Fligman I, Lonardo F, Jhanwar SC, et al. Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. Am J Pathol. 1995;147(6):1592-1599.
7. Coindre JM, Pelmus M, Hostein I, et al. Should molecular testing be required for diagnosing synovial sarcoma? A prospective study of 204 cases. Cancer. 2003;98(12):2700-2707.
8. Pérez-Losada J, Pintado B, Gutiérrez-Adán A, et al. The chimeric FUS/TLS-CHOP fusion protein specifi cally induces liposarcomas in transgenic mice. Oncogene. 2000;19(20):2413-2422.
9. Keller C, Arenkiel BR, Coffi n CM, et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 2004;18(21):2614-2626.
10. Haldar M, Hancock JD, Coffi n CM, et al. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell. 2007;11(4):375-388.
11. Verweij J, Baker LH. Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. Eur J Cancer. 2010;46(5):863-868.
12. Cancer Facts and Figures 2009. American Cancer Society: Atlanta, GA; 2009.
13. Singer S, Corson JM, Gonin R, et al. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg. 1994;219(2):165-173.
14. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specifi c death. J Clin Oncol. 2002;20(3):791-796.
15. Eilber FC, Brennan MF, Eilber FR, et al. Validation of the postoperative nomogram for 12-year sarcoma-specifi c mortality. Cancer. 2004; 101(10):2270-2275.
16. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival. A report from the Children's Oncology Group. J Clin Oncol. 2008;26(4):633-638.
17. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694-701.
18. Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to fi rst-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46(1):72-83.
19. Minchom A, Jones RL, Fisher C, et al. Clinical benefi t of secondline palliative chemotherapy in advanced soft-tissue sarcoma. Sarcoma. 2010;2010:264360.
20. Canter RJ, Qin LX, Maki RG, et al. A synovial sarcoma-specifi c preoperative nomogram supports a survival benefi t to ifosfamide-based chemotherapy and improves risk stratifi cation for patients. Clin Cancer Res. 2008;14 (24):8191-8197.
21. Karavasilis V, Seddon BM, Ashley S, et al. Signifi cant clinical benefi t of fi rst-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identifi cation of prognostic factors in 488 patients. Cancer. 2008;112(7):1585-1591.
22. Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007;246(1):105-113.
23. Pappo AS, Devidas M, Jenkins J, et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol. 2005;23(18):4031-4038.
24. Spurrell EL, Fisher C, Thomas JM, et al. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol. 2005;16(3):437-444.
25. Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101(3):627-634.
26. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas: a multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2000; 36(1):61-67.
27. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing fi rst-line regimens. A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999;17(1):150-157.
28. Wilson RE, Wood WC, Lerner HL, et al. Doxorubicin chemotherapy in the treatment of soft-tissue sarcoma. Combined results of two randomized trials. Arch Surg. 1986;121(11):1354-1359.
29. Palmerini E, Staals EL, Alberghini M, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer. 2009;115(13):2988-2998.
30. Italiano A, Penel N, Robin YM, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol. 2009;20(3):425-430.
31. Okcu MF, Despa S, Choroszy M, et al. Synovial sarcoma in children and adolescents: thirty three years of experience with multimodal therapy. Med Pediatr Oncol. 2001;37(2):90-96.
32. Keizer HJ, Crowther D, Nielsen OS, et al. EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma. Sarcoma. 1997;1(2):99-101.
33. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer. 1994; 73(10):2506-2511.
34. Kampe CE, Rosen G, Eilber F, et al. Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease. Cancer. 1993;72(7):2161-2169.
35. Schöffski P, Dumez H, Wolter P, et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2008;9(9):1609-1618.
36. Garg V, Zhang W, Gidwani P, et al. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma. Clin Cancer Res. 2007;13(18 pt 1):5446-5454.
37. Fayette J, Coquard IR, Alberti L, et al. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol. 2006;18(4):347-353.
38. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126-3132.
39. Benesch M, Windelberg M, Sauseng W, et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol. 2008;19(4):807-813.
40. Bhargava P, Marshall JL, Dahut W, et al. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin Cancer Res. 2001;7(12):3912-3919.
41. Zito RA. Synovial sarcoma: an Australian series of 48 cases. Pathology. 1984;16(1):45-52.
42. Friedrichs N, Küchler J, Endl E, et al. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol. 2008;216(4): 428-439.
43. Dobashi Y, Suzuki S, Sato E, et al. EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol. 2009;22(10):1328-1340.
44. Ray-Coquard I, Le Cesne A, Whelan JS, et al. A phase II study of gefi tinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist. 2008;13(4):467-473.
45. Olsen RJ, Lydiatt WM, Koepsell SA, et al. C-erb-B2 (HER2/ neu) expression in synovial sarcoma of the head and neck. Head Neck. 2005;27(10):883-892.
46. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody fi gitumumab (CP- 751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 2010;11(2):129-135.
47. Peng CL, Guo W, Ji T, et al. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol Ther. 2009;8(18):1729-1736.
48. Basso U, Brunello A, Bertuzzi A, et al. Sorafenib is active on lung metastases from synovial sarcoma. Ann Oncol. 2009;20(2):386-387.
49. Albritton KH, Randall RL. Prospects for targeted therapy of synovial sarcoma. J Pediatr Hematol Oncol. 2005;27(4):219-222.
50. Mancuso T, Mezzelani A, Riva C, et al. Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest. 2000;80(6):805-813.
51. Joyner DE, Albritton KH, Bastar JD, et al. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. J Orthop Res. 2006;24(3):474-480.
52. Tomek S, Koestler W, Horak P, et al. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur J Cancer. 2003;39(9):1318-1329.
53. Lubieniecka JM, de Bruijn DR, Su L, et al Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res. 2008; 68(11):4303-4310.
54. Ito T, Ouchida M, Morimoto Y, et al. Signifi cant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett. 2005;224(2):311-319.
55. Su L, Cheng H, Sampaio AV, et al. EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor. Oncogene. 2010;29(30):4352-4361.
56. Nguyen A, Su L, Campbell B, et al. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma. 2009;2009:794901.
57. DeBry RW, Seldin MF. Human/mouse homology relationships. Genomics. 1996;33(3):337-351.
58. Haldar M, Hedberg ML, Hockin MF, et al. A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. Cancer Res. 2009;69(8):3657-3664.
59. Haldar M, Hedberg M, Tvrdik P, et al. Bioluminescence based in vivo monitoring of synovial sarcomas in a genetically engineered mouse model. Proc Am Assoc Cancer Res. 2009. Abstract LB-67.